Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participants under Fed Conditions.

2024-519250-37-00 Protocol S005190-204 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 27 May 2025 · End 6 Jul 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol S005190-204

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 36
Countries 1
Sites 1

No medical condition.

Key facts

Sponsor
Institut De Recherches Internationales Servier IRIS
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
27 May 2025 → 6 Jul 2025
Decision date (initial)
2025-03-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No medical condition.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut De Recherches Internationales Servier IRIS

Sponsor organisation
Institut De Recherches Internationales Servier IRIS
Address
22 Route 128
City
Gif Sur Yvette
Postcode
91190
Country
France

Scientific contact point

Organisation
Institut De Recherches Internationales Servier IRIS
Contact name
Clinical Studies Department

Public contact point

Organisation
Institut De Recherches Internationales Servier IRIS
Contact name
Clinical Studies Department

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Ended 36 1
Rest of world 0

Investigational sites

Portugal

1 site · Ended
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Medical Management, Rua De Sarmento De Beires 153 0 Floor 3rd Floor, 4250-449, Porto

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Portugal 2025-05-27 2025-07-06 2025-05-27 2025-06-17

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-01-27 Portugal Acceptable
2025-02-26
2025-03-07
2 SUBSTANTIAL MODIFICATION SM-1 2025-04-08 Portugal Acceptable
2025-05-05
2025-05-05
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-06-04 Portugal Acceptable
2025-05-05
2025-06-04
4 NON SUBSTANTIAL MODIFICATION NSM-2 2025-06-18 Portugal Acceptable
2025-05-05
2025-06-18